Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis
about
Pharmacokinetics, efficacy and safety profiles of etanercept monotherapy in Japanese patients with rheumatoid arthritis: review of seven clinical trialsTargeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic DrugsUse of data from multiple registries in studying biologic discontinuation: challenges and opportunitiesPotential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis.Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patientsGolimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study throughProphylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study.Etanercept: a review of its use in autoimmune inflammatory diseases.Delayed anti-TNF therapy increases the risk of total knee replacement in patients with severe rheumatoid arthritis.Therapeutic management of patients with rheumatoid arthritis and associated interstitial lung disease: case report and literature review.Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies.Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan.Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan.Unaffected reaction level in tuberculin skin test by long-term therapy with tumor necrosis factor inhibitors for rheumatoid arthritis.Long-term safety and effectiveness of adalimumab for the treatment of Japanese patients with rheumatoid arthritis: 3-year results from a postmarketing surveillance of 552 patients.Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: Results from the prospective post-marketing surveillance.Trend of patient characteristics and its impact on the response to adalimumab in patients with rheumatoid arthritis: post hoc time-course analysis of an all-case PMS in Japan.Use of anti-tumor necrosis factor biologics in the treatment of rheumatoid arthritis does not change human T-lymphotropic virus type 1 markers: a case series.Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients.RETRACTED ARTICLE: Safety and effectiveness of high-dose methotrexate (over 8 mg/week) in 2838 Japanese patients with rheumatoid arthritis: A postmarketing surveillance report.Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012.Safety and efficacy of fesoterodine fumarate in patients with overactive bladder: results of a post-marketing surveillance study in Korea.Whole genome analysis on the genetic backgrounds associated with the secondary failure to etanercept in patients with rheumatoid arthritis.A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and Japan.
P2860
Q27015772-6D64DF49-8D10-45D9-BD00-ADD094277D36Q28073436-95F5DBD8-C47F-4F78-A8FE-8E0B9F5BF3AEQ30678187-651A08AF-B171-441E-9959-24F3FC5C750AQ34071762-E2A23799-CBF6-41D8-A8D2-5B1AE982225FQ35540000-397678D4-9620-41B6-ABB9-F6478F462248Q37130039-B2520A0E-E9C8-49C6-B3B7-F8BA43D0CC59Q37690719-6025DA58-373A-4C8A-96FC-146F62B0E658Q38230740-7ECFE97E-D20C-4F21-9AE5-678EDC529E4DQ38648496-7DDC871E-85AB-4AD7-8E54-D663CFA8DDAAQ38979114-9AFED846-951D-45EB-8936-D532D7547C82Q39100810-C8F38F00-9DCF-481A-B0FD-EB13766894E5Q39129677-FC4BCD7B-F68D-4DBD-B1CA-46A0CA94D35DQ40000074-A4F63B12-EE50-48D5-B164-A5A12EE08E5EQ40206145-4DA33E96-7243-4A57-9D46-D4B7A173DBE6Q40253228-3063BA0E-6684-4212-9617-C9615881A8F0Q40857120-AED97D5B-8F7D-4A6D-A21B-E012565D7EC4Q41610320-367F47E6-2AAD-45D0-88A1-4620D4A4BF70Q42240087-0A8E3762-A1BC-4594-8D8E-35738C208B37Q45098990-936F1203-7287-4CAF-B2A8-BDA439ECD55CQ48615436-84A80289-AF30-46DF-92A2-10AA4DD2E69AQ50591145-2F2FF50B-6EDC-4BAD-B942-2D5491242AD8Q51392015-23E9F2D0-6499-42A5-AEB1-C9B88AFA855CQ51641849-32B399FA-DEF6-4DEC-B34B-F3708AA29729Q54469391-633BEE2A-BF21-4ECD-9430-78DCF97E546C
P2860
Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Postmarketing surveillance of ...... ents with rheumatoid arthritis
@ast
Postmarketing surveillance of ...... ents with rheumatoid arthritis
@en
type
label
Postmarketing surveillance of ...... ents with rheumatoid arthritis
@ast
Postmarketing surveillance of ...... ents with rheumatoid arthritis
@en
prefLabel
Postmarketing surveillance of ...... ents with rheumatoid arthritis
@ast
Postmarketing surveillance of ...... ents with rheumatoid arthritis
@en
P2093
P2860
P1433
P1476
Postmarketing surveillance of ...... ents with rheumatoid arthritis
@en
P2093
Bruce Freundlich
Hisashi Yamanaka
Junnosuke Ryu
Koichi Fujii
Masayoshi Harigai
Michio Suzukawa
Naoki Ishiguro
Shigeko Inokuma
Takunari Yoshinaga
Tsutomu Takeuchi
P2860
P304
P356
10.3109/S10165-010-0406-3
P50
P577
2011-01-25T00:00:00Z